Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide in unresectable stage III NSCLC
NCT00157196Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2005
- Primary completion
- Sep 2007
01
Overview
Phase 2, open-label, single-arm trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoint: Treatment Emergent Adverse Events at 29 months. Started Apr 2005; status: completed.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00157196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157196.